yahoo_financeOriginal article
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Phase 3Positive
AI Analysis
Summary
Immunic is advancing its MS drug toward Phase 3 data readout, with results expected by year-end 2026. The company has progressed the development program and anticipates releasing key efficacy and safety data in the coming months.
Clinical Trial Data
Phase
Phase 3
Importance:7/10
Sentiment:
0.60
Phase 3Multiple SclerosisClinical TrialData Expected
Related Companies
Read the original article
Published by yahoo_finance on August 11, 2026 12:36 PM